-
公开(公告)号：US20210251889A1
公开(公告)日：2021-08-19
申请号：US17177797
申请日：2021-02-17
申请人： Nevakar Inc.
摘要： Storage stable sterile ready-to-administer formulations comprising N-acetylcysteine are presented with desirable stability characteristics. In preferred aspects, formulations comprise low quantities of one or more chelating agents, contain N-acetylcysteine at a concentration of 25 mg/mL or 50 mg/mL, and are packaged in a suitable format, such as a polymeric bag with a metalized overwrap and a non-contact oxygen scavenger.
-
公开(公告)号：US20210228507A1
公开(公告)日：2021-07-29
申请号：US17154516
申请日：2021-01-21
申请人： Nevakar Inc.
IPC分类号： A61K31/137 , A61K47/12 , A61K47/18 , A61K47/02 , A61K9/00 , B65D81/26 , B65D75/38 , B65B3/00
摘要： A ready-to-administer antioxidant free phenylephrine compositions has improved stability and is optionally free of metal chelating agents. Contemplated compositions are preferably packaged into a flexible polymer bag and maintain degradation of the phenylephrine at remarkably low levels, even over extended storage periods.
-
公开(公告)号：US10471026B2
公开(公告)日：2019-11-12
申请号：US16163476
申请日：2018-10-17
申请人： Nevakar, Inc.
IPC分类号： A61K31/137 , A61K9/00 , A61P9/02 , A61K47/12 , A61K47/18
摘要： The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.
-
公开(公告)号：US20190133981A1
公开(公告)日：2019-05-09
申请号：US16091614
申请日：2017-04-07
申请人： NEVAKAR INC
发明人： Varun KHURANA , Vlvek Yadav , Jack Martin Lipman , Tao Zhang , Iouri V. Illtchev , Tushar Hingorani , Navneet Puri , Kumaresh Soppimath
IPC分类号： A61K31/195 , A61K9/00 , A61K31/197 , A61K31/167
摘要： Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.
-
公开(公告)号：US20190133972A1
公开(公告)日：2019-05-09
申请号：US16239461
申请日：2019-01-03
申请人： Nevakar, Inc.
IPC分类号： A61K31/137 , A61P9/02 , A61K47/12 , A61K47/18 , A61K9/00
摘要： The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.
-
公开(公告)号：US20210259994A1
公开(公告)日：2021-08-26
申请号：US17179078
申请日：2021-02-18
申请人： Nevakar Inc.
IPC分类号： A61K31/137 , A61K9/08 , A61K47/54 , A61L2/00
摘要： Storage stable aqueous ready-to-administer formulations comprising isoproterenol are presented with desirable stability characteristics. In preferred aspects, formulations are terminally sterilized and packaged in a suitable format, such as a polymeric bag with metalized overwrap and include a non-contact oxygen scavenger.
-
公开(公告)号：US20210128546A1
公开(公告)日：2021-05-06
申请号：US17145589
申请日：2021-01-11
申请人： Nevakar Inc.
摘要： The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.
-
公开(公告)号：US20210128507A1
公开(公告)日：2021-05-06
申请号：US17098923
申请日：2020-11-16
申请人： NEVAKAR Inc.
发明人： Varun Khurana , Vivek Yadav , Jack Martin Lipman , Tao Zhang , Iouri V. Ilitchev , Tushar Hingorani , Kumaresh Soppimath , Navneet Puri
IPC分类号： A61K31/195 , A61K9/00 , A61K31/167 , A61K45/06 , A61K31/197
摘要： Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.
-
公开(公告)号：US20210121395A1
公开(公告)日：2021-04-29
申请号：US17142744
申请日：2021-01-06
申请人： Nevakar Inc.
IPC分类号： A61K9/00 , A61M5/145 , A61K47/02 , A61M25/00 , A61K31/225 , A61M5/31 , A61K47/12 , A61M5/178 , A61M39/10 , A61K31/137
摘要： Pre-filled syringes, pharmaceutical compositions, and kits and methods relating to same allow for emergency administration of one or more drugs from prefilled glass syringes to a patient via a needleless connector. In preferred embodiments, the prefilled glass syringe has a drug volume of at least 5 mL, has a Luer-lock, and has a syringe tip with an internal channel that has a diameter of about 1.7 mm. Such syringes advantageously allow storage of emergency drugs without leaching of plastic materials and degradation, and substantially improve the safety profile where the syringe is attached to an IV line via a needleless connector.
-
公开(公告)号：US20200246294A1
公开(公告)日：2020-08-06
申请号：US16644022
申请日：2018-09-27
申请人： Nevakar Inc.
IPC分类号： A61K31/197 , A61K31/167 , A61K31/192 , A61K45/06
摘要： Fixed-dose combination drugs comprising an NSAID as a first drug component and a GABA-type calcium channel blocker as a second drug component are contemplated. Further contemplated aspects also include methods of administration of combination drugs and drugs contained herein.
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.039 秒)
